Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Prostatic Neoplasms 6Neuroendocrine Tumors 2Urogenital Neoplasms 1Prostatic Diseases 1Oligometastatic Prostate Cancer (OMPC) 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Carcinoma, Merkel Cell 1Carcinoma 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

pembrolizumab 6avelumab 6Nivolumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 3Biopsy 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Prednisone 2Ipilimumab 2CTLA-4 Antigen 2talimogene laherparepvec 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1aldesleukin 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1Radiosurgery 1MAPRE1 protein, human 1Lutetium-177 1Laparoscopy 1Exercise Test 1Cyclophosphamide 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Lutetium-177 × 90 days × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡